FULVESTRANT ACCORD fulvestrant 250 mg/5 mL solution for injection pre-filled syringe Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

fulvestrant accord fulvestrant 250 mg/5 ml solution for injection pre-filled syringe

accord healthcare pty ltd - fulvestrant, quantity: 250 mg - injection, solution - excipient ingredients: benzyl alcohol; castor oil; benzyl benzoate; ethanol - fulvestrant accord is indicated for the treatment of postmenopausal women with: ? hormone-receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, locally advanced or metastatic breast cancer who have not been previously treated with endocrine therapy. ? hr positive, locally advanced or metastatic breast cancer who have progressive disease following prior endocrine (anti-oestrogen or aromatase inhibitor) therapy.

DEXMEDETOMIDINE ACCORD dexmedetomidine (as hydrochloride) 200 micrograms/2 mL injection vial Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

dexmedetomidine accord dexmedetomidine (as hydrochloride) 200 micrograms/2 ml injection vial

accord healthcare pty ltd - dexmedetomidine hydrochloride, quantity: 118 microgram/ml (equivalent: dexmedetomidine, qty microgram/ml) - injection, concentrated - excipient ingredients: sodium chloride; water for injections - icu sedation: for sedation of initially intubated adult patients during treatment in an intensive care setting. the use of dexmedetomidine accord by continuous infusion in these patients should not exceed 24 hours.,procedural sedation: for sedation of non-intubated adult patients prior to and/or during surgical and other procedures.